Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
The revolution is about to be televised… on Hulu. The Handmaid’s Tale has (rivetingly) been scaring the sh*t out of audiences since 2017 with frozen bank accounts, sewn-up mouths, a drowned Sydney ...
Can Gilead be held accountable for holding back the sale of an HIV drug it allegedly knew was safer than its blockbuster predecessor? The answer could offer a unique example of a situation where a ...
We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at ...
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...
Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...
Clinical Trials Arena on MSN15h
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I successGilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
Marilyn Weiler treated the Monday Senior Lunch Bunch to an hour of curious and humorous bird sayings and expressions on Feb.
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback